Top Page
Amplia Therapeutics
(OTC:ATX)
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Amplia Therapeutics Business Overview & Revenue Model
Amplia Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.78M | 3.78M | 4.45M | 1.19M | 1.98M | 1.53M |
| Gross Profit | 3.57M | 3.57M | 4.01M | 1.12M | 1.98M | 1.53M |
| EBITDA | -6.78M | -6.78M | -4.48M | -7.26M | -3.64M | -3.81M |
| Net Income | -6.57M | -6.57M | -4.50M | -6.24M | -3.64M | -2.28M |
Balance Sheet | ||||||
| Total Assets | 22.94M | 22.94M | 14.85M | 18.68M | 24.48M | 10.88M |
| Cash, Cash Equivalents and Short-Term Investments | 10.86M | 10.86M | 3.39M | 9.26M | 14.61M | 1.85M |
| Total Debt | 13.89K | 13.89K | 1.59M | 2.27M | 2.10M | 0.00 |
| Total Liabilities | 1.91M | 1.91M | 3.43M | 2.85M | 2.64M | 539.13K |
| Stockholders Equity | 21.02M | 21.02M | 11.42M | 15.84M | 21.85M | 10.34M |
Cash Flow | ||||||
| Free Cash Flow | -6.89M | -6.89M | -5.13M | -5.31M | -4.42M | -2.92M |
| Operating Cash Flow | -6.89M | -6.89M | -5.13M | -5.29M | -4.40M | -2.92M |
| Investing Cash Flow | -2.07K | -2.07K | -2.23K | -58.42K | -26.64K | -5.35K |
| Financing Cash Flow | 14.32M | 14.32M | -772.98K | -84.22K | 17.19M | 3.66M |
Amplia Therapeutics Technical Analysis
Amplia Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$22.04M | ― | -143.71% | ― | 306.88% | ― | |
45 Neutral | AU$64.13M | ― | -27.39% | ― | ― | 26.64% | |
40 Underperform | AU$17.03M | -7.94 | -1651.76% | ― | -100.00% | 2.86% | |
37 Underperform | AU$6.62M | ― | -628.72% | ― | ― | 31.87% | |
36 Underperform | AU$26.89M | -5.51 | -157.93% | ― | ― | -36.89% |
Amplia Therapeutics Corporate Events
Amplia Therapeutics has announced its financial report for the half year ending September 2025, highlighting significant progress in its clinical trials. The company’s lead drug, narmafotinib, has shown promising results in the ACCENT trial for advanced pancreatic cancer, achieving a confirmed response rate of 33%, which is superior to existing treatments. A new trial, AMPLICITY, has also commenced, further exploring narmafotinib’s efficacy in combination with FOLFIRINOX.
Amplia Therapeutics has received positive feedback from the US FDA regarding its planned Phase 2b/3 trial for narmafotinib, a FAK inhibitor, in combination with gemcitabine and Abraxane for pancreatic cancer. The FDA’s support for the dose comparison design and minimal impact on timelines enhances Amplia’s confidence in proceeding with the trial, which is set to begin in late 2026, potentially strengthening its position in the oncology market.
Amplia Therapeutics Limited has announced the issuance of 480,769 unquoted equity securities in the form of Zero Exercise Price Options under an employee incentive scheme. This strategic move is likely aimed at retaining and motivating employees, potentially impacting the company’s operational efficiency and competitive positioning in the biotechnology sector.
Amplia Therapeutics has commenced trading on the U.S. OTCQB Venture Market, enhancing its engagement with U.S. investors and expanding its presence in the U.S. market. This move coincides with the company’s AMPLICITY clinical trial for advanced pancreatic cancer opening at five sites in the U.S., and is part of Amplia’s broader strategy to educate investors about its FAK inhibitor program, which includes the promising drug narmafotinib.
Amplia Therapeutics has reported significant progress in its clinical trials for narmafotinib, a FAK inhibitor, showing improved outcomes in metastatic pancreatic cancer treatment. The company has achieved key regulatory milestones, including ethics approval for a new trial combining narmafotinib with FOLFIRINOX chemotherapy and securing a patent for its drug formulation, positioning it for further commercial development and potential partnerships.
Amplia Therapeutics has received a $3.77 million R&D tax rebate from the Australian Tax Office, which will support the progression of its clinical trials for narmafotinib, a FAK inhibitor. This funding will aid in advancing the ACCENT and AMPLICITY trials, which are exploring narmafotinib’s effectiveness in treating advanced pancreatic cancer, potentially enhancing Amplia’s position in the oncology pharmaceutical industry.
Amplia Therapeutics is expanding its U.S. presence by increasing investor engagement and awareness through a capital markets campaign. This initiative supports its ongoing Phase 2A clinical trial for pancreatic cancer and includes plans to uplist to the OTCQB market, aiming to broaden its U.S. investor base and enhance its market positioning.
Amplia Therapeutics has announced promising results from its ACCENT clinical trial, which tests the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has shown an improved Objective Response Rate of 33% compared to 23% with chemotherapy alone, and a mean duration on trial of 219 days, indicating enhanced efficacy and durability. Narmafotinib continues to demonstrate good tolerability, with no significant increase in chemotherapy-related side effects, positioning Amplia favorably in the cancer treatment landscape.
Amplia Therapeutics Limited announced the cessation of 5,626,000 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategies and future growth prospects.
Amplia Therapeutics has announced that the US Patent Office has allowed a key patent for its FAK inhibitor, narmafotinib, with a formal grant expected soon. This patent, already granted in several countries, extends narmafotinib’s protection until at least 2040, enhancing its commercial value. The patent describes a stable form of narmafotinib, which is being used in clinical trials for advanced pancreatic cancer, showing promising results. This development strengthens Amplia’s intellectual property portfolio and positions the company favorably in the pharmaceutical industry, particularly in the field of cancer treatment.
Amplia Therapeutics Limited announced a change in the director’s interest for Dr. Warwick Tong, as reflected in the attached Appendix 3Y. This update involves changes in the allotment and expiry of shares and options held by Dr. Tong. Such changes in director’s interests can impact stakeholder perceptions and reflect internal strategic adjustments within the company.
Amplia Therapeutics Limited has announced a change in the director’s interest notice for Dr. Christopher Burns, reflecting updates in his securities holdings. This announcement, authorized by the company’s secretary, highlights the ongoing management and regulatory compliance within the company, potentially impacting investor perceptions and stakeholder confidence.
Amplia Therapeutics Limited announced a change in the director’s interest notice for Dr. Robert Peach, reflecting a recent allotment of shares and options, as well as the expiry of certain options. This update is part of the company’s regulatory compliance and may impact the company’s stock dynamics and stakeholder interests.
Amplia Therapeutics Limited has announced a change in the director’s interest notice for Jane Bell, reflecting recent changes in her holdings of shares and options. This update is part of the company’s ongoing compliance with ASX listing rules and demonstrates transparency in its corporate governance practices.
Amplia Therapeutics Limited has announced the cessation of 2,355,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This announcement may impact the company’s capital structure but does not indicate any immediate operational changes or strategic shifts.